By: Mohammad Hassan Bagheri
Understanding Tumor-Related Epilepsy in Gliomas: A Multidisciplinary Perspective
Imagine a patient named Sarah, a 35-year-old teacher, who begins experiencing unexplained seizures. After a series of tests, she is diagnosed with a glioma—a type of brain tumor. This diagnosis brings not only the fear of cancer but also the challenge of managing epilepsy. Sarah’s story is not unique; many patients with gliomas face similar struggles. Seizures are a common and often difficult-to-treat symptom in brain tumor patients, occurring in approximately 60% of cases. For patients like Sarah, understanding and managing tumor-related epilepsy (TRE) is crucial to improving both survival and quality of life.
A recent multidisciplinary study published in Epilepsia provides a comprehensive overview of TRE in gliomas, offering insights that could transform the lives of patients like Sarah. This summary distills the study’s key findings, making them accessible to both healthcare professionals and the general public, while highlighting the real-world impact on patients, families, and medical practice.
The Science Behind Seizures in Gliomas:
Gliomas are a diverse group of brain tumors that can disrupt the brain’s normal functioning, leading to seizures. Think of the brain as a complex network of electrical circuits. In a healthy brain, these circuits are balanced, allowing for smooth communication between neurons. However, when a glioma develops, it disrupts this balance. The tumor alters the local environment, making neurons more excitable and prone to firing abnormally—resulting in seizures.
Recent research has uncovered that specific genetic mutations in gliomas, such as BRAF V600E and IDH, play a significant role in this process. These mutations not only drive tumor growth but also enhance the brain’s susceptibility to seizures. The 2021 World Health Organization (WHO) classification of brain tumors emphasizes these molecular profiles, helping clinicians identify which gliomas are most likely to cause epilepsy. For instance, low-grade gliomas with IDH mutations are often associated with a higher risk of seizures. Understanding these markers is crucial for tailoring treatment and predicting outcomes.
A Multidisciplinary Approach to Treatment
Managing TRE requires a collaborative effort from neurologists, oncologists, neurosurgeons, and other specialists. The study outlines several key treatment strategies, each with the potential to improve both tumor control and seizure management:
Surgery: For many patients, surgery is the first line of treatment. The goal is to remove as much of the tumor as possible while preserving healthy brain tissue. Advanced techniques like electrocorticography (ECoG) allow surgeons to map the brain’s electrical activity during the operation, identifying highly epileptogenic areas. By targeting these regions, surgeons can improve the chances of seizure freedom post-surgery. However, complete removal isn’t always possible, especially in high-grade gliomas, which are more aggressive and infiltrative.
Radiotherapy and Chemotherapy: When surgery isn’t feasible or as a follow-up treatment, radiotherapy and chemotherapy come into play. Radiotherapy uses targeted radiation to kill tumor cells, while chemotherapy, particularly with drugs like temozolomide (TMZ), helps control tumor growth. Interestingly, these treatments can also reduce seizure frequency, especially in tumors with specific genetic profiles, such as IDH-mutated gliomas. This dual benefit is vital for improving both survival and quality of life.
Antiseizure Medications (ASMs): ASMs are the cornerstone of epilepsy management in glioma patients. While older drugs like phenytoin and carbamazepine have been used, newer medications such as levetiracetam and perampanel are preferred due to their better tolerability and fewer interactions with other treatments. Perampanel, in particular, has shown promise in drug-resistant TRE, offering hope to patients who don’t respond to initial therapies.
Each treatment plan must be personalized, taking into account the patient’s age, tumor characteristics, and overall health. For elderly patients or those in advanced stages of the disease, balancing efficacy with quality of life is especially important.
The Impact of Seizures on Prognosis
Seizures in glioma patients are more than just a symptom—they can influence the course of the disease. The study highlights that patients who continue to experience seizures after treatment, particularly in diffuse low-grade gliomas (DLGGs), have poorer survival outcomes. This suggests that seizures might not only reflect the tumor’s presence but could also contribute to its progression. Achieving and maintaining seizure control is therefore critical, not just for daily functioning but potentially for slowing the disease itself.
For patients like Sarah, this means that effective seizure management could be a key factor in her long-term prognosis. It also underscores the importance of early intervention and continuous monitoring throughout the treatment journey.
Looking Ahead: The Need for Further Research
While significant progress has been made in understanding and treating TRE, many questions remain. The study calls for more prospective, multicentric research to refine therapeutic strategies and improve patient outcomes. By supporting such research, we can hope to offer better futures to patients like Sarah, enabling them to live fuller, seizure-free lives.
Conclusion: A Message of Hope and Collaboration
Tumor-related epilepsy in gliomas is a complex challenge, but advancements in multidisciplinary care are bringing new hope. From molecular insights to personalized treatment plans, the latest research offers a roadmap for improving both survival and quality of life. For patients, families, and healthcare providers, this study serves as a reminder of the power of collaboration and innovation in the fight against epilepsy and brain tumors.
At The Defeating Epilepsy Foundation, we are committed to sharing knowledge that empowers and inspires. By understanding the science behind TRE and the importance of a team-based approach, we can work together to defeat epilepsy and improve the lives of those affected by brain tumors.
Resources:
Michelucci, R., Pauletto, G., Silvani, A., Pasini, E. Ius, T., Martinoni, M., Castioni, C.A., Salmaggi, A., Asioli, S., Maschio, M., Minniti, G., Franceschi, E., Villani, F., Ruda, R., Aronica, E. (2025). Tumor-related epilepsy in giloma: A multidisciplinary overview. Epilepsia. Retrieved from: doi:10.1111/epi.18523
